Latest News

BioStock’s article series on autoimmune disease: Drug Development for RA and MS

BioStock published an article on 4 July 2019 about autoimmune diseases, which can be read in full below. Therapies for autoimmune diseases are available but do not work for all patients, and when they do, side effects can be severe. There is a strong need for new therapies and therefore there is a large market […]

Read More

Article in BioStock: World MS Day: Cyxone aims to deliver better, safer treatments to multiple sclerosis patients

BioStock published an article about Cyxone on 29 May 2019, which can be read below. As mainstream MS treatments get scolded by the FDA and the EMA after reports from patients experiencing severe side effects, the market for safer, more effective MS drugs is growing. On Monday, Swedish Cyxone submitted the application to start a […]

Read More

Pharmaceutical Business Review: Cyxone MS drug T20K succeeds in preclinical program

Cyxone MS drug T20K succeeds in preclinical program Cyxone said that T20K, its investigational drug for the treatment of multiple sclerosis (MS), has succeeded in a preclinical program by yielding positive results in the toxicology studies. According to Cyxone, T20K during the preclinical program has been shown to be safe for people to ingest. The […]

Read More

MedUni Vienna technology wins Recognition Prize in the science2business awards

A joint project between MedUni Vienna and Freiburg University Hospital, using cyclotides as a treatment for multiple sclerosis, was awarded the Recognition Prize in the science2business awards. This development is an example of a successful transfer of innovation from research to the business world. Read the article published on Medical University of Vienna’s homepage

Read More

Multiple sclerosis: plant peptide could prevent onset of the disease

MedUni Vienna has made a crucial development in the treatment of Multiple Sclerosis (MS): Together with his team and the research group led by Gernot Schabbauer, international partners from Australia, Germany and Sweden, Christian Gruber, Chief Researcher at the Center for Physiology and Pharmacology has demonstrated in an animal model that, following treatment with a […]

Read More